Evidence map›Paper›PMID 40966023›Full record

Observational studyScience progress

Effects of chemoradiotherapy on plasma oncogenic miRNAs as biomarkers in cervical cancer patients: A prospective observational study.

Masoumeh Parvizi, Mohammad Taghizadeh-Teymorloei, Maryam Vaezi, Masoumeh Bakhshandeh, Noushin Mobaraki-Asl, Ebrahim Esmati, Reza Eghdam-Zamiri, Farhad Jeddi, Abbas Karimi

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Masoumeh ParviziDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0009-0007-8509-2993
Mohammad Taghizadeh-TeymorloeiDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0009-0009-3489-5993
Maryam VaeziObstetric and Oncology Department, School of Medicine, Women's Reproductive Health Research Center, Clinical Research Institute, Alzahra Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0000-0002-5975-3889
Masoumeh BakhshandehObstetric and Oncology Department, School of Medicine, Women's Reproductive Health Research Center, Clinical Research Institute, Alzahra Hospital, Tabriz University of Medical Sciences, Tabriz, Iran.
Noushin Mobaraki-AslDepartment of Obstetrics and Gynecology, School of Medicine, Alavi Hospital, Ardabil University of Medical Sciences, Ardabil, Iran.
Ebrahim EsmatiDepartment of Radiation Oncology, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
Reza Eghdam-ZamiriDepartment of Radiation Oncology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.
Farhad JeddiDepartment of Genetics and Pathology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.
Abbas KarimiDepartment of Molecular Medicine, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.ORCID 0000-0002-1172-8502

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundCervical cancer (CC) is a leading cause of death among women worldwide, predominantly driven by high-risk human papillomavirus infection. MicroRNAs (miRNAs) regulate gene expression and may serve as noninvasive biomarkers for diagnosis, prognosis, and treatment monitoring in CC.ObjectiveThis study aimed to identify circulating miRNAs linked to HPV-related CC and evaluate their potential as biomarkers for prognosis and response to concurrent chemoradiotherapy (CRT).MethodsIn this prospective study, plasma samples from 36 CC patients were collected before and after treatment. Five miRNAs (hsa-miR-1-3p, hsa-miR-10a-5p, hsa-miR-34a-5p, hsa-miR-34c-5p, and hsa-miR-409-3p) were selected via literature review and pathway analysis. miRNA levels were quantified by quantitative polymerase chain reaction and normalized to hsa-miR-16. Associations with clinicopathological features and survival were analyzed statistically.ResultsPathway analysis confirmed the involvement of selected miRNAs in cancer and HPV-related pathways, including PI3K-Akt and MAPK signaling. Post-CRT, significant downregulation of hsa-miR-34a-5p, hsa-miR-34c-5p, and hsa-miR-409-3p was observed (

Indexed as

Biomarkers, TumorChemoradiotherapyMicroRNAsUterine Cervical NeoplasmsAdultAgedFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedPapillomavirus InfectionsPrognosisProspective StudiesBiomarkers, TumorMicroRNAscervical cancerchemoradiotherapyMicroRNAplasma biomarkers

Identifiers

PMID40966023
PMCPMC12446803

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.